Close Menu

NEW YORK (GenomeWeb) – The German Federal Joint Committee (G-BA), the authority that decides which therapies and medical services are covered under Germany's public health insurance system, said yesterday that it has commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to evaluate additional study results on the use of biomarker-based tests in primary breast cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.